The main Semax news is a July 24 advisory vote supporting its addition to a federal compounding list. Compounding means preparing a medicine for an individual prescription. FDA staff had recommended against that step. The vote did not approve Semax as a medicine, and the published list still does not include it.

Changelog

July 24, 2026 — FDA's advisory panel recommended listing Semax.

The Pharmacy Compounding Advisory Committee (PCAC), an expert panel that advises FDA, supported adding both forms of Semax to the 503A Bulks List. That list covers ingredients for certain medicines prepared for individual prescriptions. The forms were free base, the compound without an added salt, and acetate, a salt form.

The official FDA webcast records the recommendations for both forms. The direction differed from FDA staff's review, dated May 11, 2026, which recommended against adding either. Staff found gaps in evidence for benefit, safety, and product quality.

As of September 30, 2026, the day this article was written, the July vote remains an advisory recommendation. Changing the list requires FDA's rulemaking process, a formal process for changing a federal rule. The panel recommendation is the quarter's main change.

What the Semax news means for a prescription

Semax is a synthetic peptide, a short chain of amino acids, the building blocks of proteins. It has been studied for brain and nerve-related conditions. The guide to what Semax is used for separates those uses from broader claims about focus.

Semax is not FDA-approved, and compounded Semax / Selank is not FDA-approved either. A favorable advisory vote does not establish a product's benefits or safety. Under applicable compounding rules, a licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.

Promise's Semax / Selank product page lists a compounded injectable — 1 mg / 1 mg per mL × 5 mL vial (5 mg Semax + 5 mg Selank) — offered after a licensed provider reviews your request; standalone Semax is coming soon to Promise — add me to the list. The blend is a separate preparation, so findings about Semax alone do not automatically describe it.

Where the federal list stands

Semax does not appear among the ingredients in the current federal regulation, 21 CFR 216.23. The site showed the text as up to date through September 28, 2026. That date describes the site's currency, rather than a new Semax decision.

A recommendation about an ingredient does not settle the details of a finished bottle. Its other ingredients and delivery method still matter.

The Semax FDA history follows the earlier nominations and reviews.

A 2026 eye study adds context

A study published June 29, 2026, in Vestnik Oftalmologii followed 42 patients after surgery for retinal detachment. That is when the eye's light-sensing layer separates from the tissue underneath.

Both groups received Semax. One also received a helium-and-oxygen breathing treatment and a different nasal delivery method. Researchers reported better recovery of vision measures in that combined-treatment group by six months.

The study followed patients for 12 months; that does not mean they took Semax continuously for a year. Because both groups received it, the study cannot isolate Semax's contribution. It adds information about a specific recovery setting, without answering whether Semax improves everyday concentration or whether a Semax / Selank blend has the same effects.

What brain imaging says about the pair

An earlier 2020 study in Doklady Biological Sciences involved 52 healthy participants. They received Semax, Selank, or placebo, a comparison preparation without either peptide. They did not receive the two peptides together.

Researchers used fMRI, a scan that tracks changes associated with brain activity. Scans before treatment and at five and 20 minutes afterward found changes in how certain brain regions worked together.

Those were short-term scan findings. They did not establish better concentration through a workday or lasting improvement in memory. They also do not test Promise's injectable blend. A provider considers the specific formulation. Putting two studied ingredients together does not establish that the combination has been studied.

What a provider considers now

The starting point is the problem someone hopes to address. A recent change in attention, persistent fatigue, and a diagnosed neurological condition raise different questions. Sleep, other medicines, and existing treatment matter before a peptide is considered.

FDA's staff review also leaves practical questions about the preparation itself. It found no human studies measuring how Semax moves through the body. It raised questions about ingredient quality and how consistently a nasal pump delivers the liquid. A committee recommendation does not fill those gaps.

For a visit, useful questions include:

  • What evidence fits the condition being discussed?
  • Does that evidence concern one peptide or the blend?
  • What ingredients and delivery method would the prescription specify?
  • What would follow-up measure, and when would the plan be reviewed?

A prescription should connect the medication with a named clinician, an identified dispensing pharmacy, clear labeling, and a way to report problems. Those details provide someone to contact when a question comes up. They do not guarantee that a treatment will help.

The Semax side-effects guide covers the safety discussion in more detail. The prescriber sets the actual dose and follow-up plan. A licensed provider reviews every request, and not everyone qualifies.

What would change the next update

A published FDA proposal or final rule would be a concrete regulatory development. Its wording would matter: which form it covers, what changed, and when the change takes effect. The July recommendation alone supplies none of those answers.

For the evidence, a useful next step would be a comparison study measuring outcomes people notice in daily life. It would need to identify the preparation, track unwanted effects, and follow participants long enough to assess the result. Separate testing of a blend would answer a different question from testing either ingredient alone.

A future update can compare those developments with today's position. For now, a consultation begins with the person's goals, the actual preparation, and what the evidence can reasonably support.